CNS Pharmaceuticals, Inc. Operating Cash Flow
CNS Pharmaceuticals, Inc. (CNSP) reported Operating Cash Flow of -$8.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.54M.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.65M.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.05M.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.17M.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$13.81M.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$17.11M.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$14.14M.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$10.56M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$8.19M 10-Q · filed 2026-08-12 | -$11.24M derived: sum of 3 quarters · filed 2026-08-12 | -$13.41M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$4.65M 10-Q · filed 2026-05-14 | -$7.70M derived: sum of 2 quarters · filed 2026-05-14 | -$9.87M derived: sum of 3 quarters · filed 2026-05-14 | -$15.22M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.23M derived: sum of 2 quarters · filed 2026-03-31 | -$10.57M derived: sum of 3 quarters · filed 2026-08-12 | -$13.81M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$7.52M derived: sum of 2 quarters · filed 2026-08-12 | -$10.76M 10-Q · filed 2025-11-14 | -$16.23M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$5.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$8.59M 10-Q · filed 2026-08-12 | -$8.59M 10-Q · filed 2025-08-14 | -$14.06M derived: sum of 3 quarters · filed 2026-08-12 | -$20.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$3.24M 10-Q · filed 2026-05-14 | -$8.71M derived: sum of 2 quarters · filed 2026-05-14 | -$15.51M derived: sum of 3 quarters · filed 2026-05-14 | -$17.16M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$12.27M derived: sum of 2 quarters · filed 2026-03-31 | -$13.92M derived: sum of 3 quarters · filed 2026-03-31 | -$17.11M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$8.45M derived: sum of 2 quarters · filed 2025-11-14 | -$11.64M 10-Q · filed 2025-11-14 | -$14.18M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.84M 10-Q · filed 2025-08-14 | -$7.38M derived: sum of 3 quarters · filed 2025-08-14 | -$10.76M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$3.19M 10-Q · filed 2025-05-15 | -$5.73M derived: sum of 2 quarters · filed 2025-05-15 | -$9.10M derived: sum of 3 quarters · filed 2025-05-15 | -$12.51M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$5.91M derived: sum of 2 quarters · filed 2025-03-31 | -$9.32M derived: sum of 3 quarters · filed 2025-03-31 | -$14.14M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$6.78M derived: sum of 2 quarters · filed 2024-11-14 | -$11.60M 10-Q · filed 2024-11-14 | -$13.91M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$8.23M 10-Q · filed 2024-08-14 | -$10.53M derived: sum of 3 quarters · filed 2024-08-14 | -$12.35M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$4.82M 10-Q · filed 2024-05-15 | -$7.13M derived: sum of 2 quarters · filed 2024-05-15 | -$8.94M derived: sum of 3 quarters · filed 2024-05-15 | -$12.31M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$4.12M derived: sum of 2 quarters · filed 2024-04-01 | -$7.48M derived: sum of 3 quarters · filed 2024-04-01 | -$10.56M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$5.18M derived: sum of 2 quarters · filed 2023-11-14 | -$8.25M 10-Q · filed 2023-11-14 | -$11.49M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$6.44M 10-Q · filed 2023-08-14 | -$9.68M derived: sum of 3 quarters · filed 2023-08-14 | -$11.67M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$3.08M 10-Q · filed 2023-05-15 | -$6.31M derived: sum of 2 quarters · filed 2023-05-15 | -$8.31M derived: sum of 3 quarters · filed 2023-05-15 | -$13.31M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$5.23M derived: sum of 2 quarters · filed 2023-03-31 | -$10.23M derived: sum of 3 quarters · filed 2023-03-31 | -$13.54M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$6.99M derived: sum of 2 quarters · filed 2022-11-10 | -$10.30M 10-Q · filed 2022-11-10 | -$11.75M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$8.31M 10-Q · filed 2022-08-12 | -$9.75M derived: sum of 3 quarters · filed 2022-08-12 | -$11.03M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$3.31M 10-Q · filed 2022-05-13 | -$4.75M derived: sum of 2 quarters · filed 2022-05-13 | -$6.03M derived: sum of 3 quarters · filed 2022-05-13 | -$8.77M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$2.72M derived: sum of 2 quarters · filed 2022-03-03 | -$5.46M derived: sum of 3 quarters · filed 2022-03-03 | -$7.32M 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$4.02M derived: sum of 2 quarters · filed 2021-11-12 | -$5.87M 10-Q · filed 2021-11-12 | -$8.35M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$4.60M 10-Q · filed 2021-08-13 | -$7.07M derived: sum of 3 quarters · filed 2021-08-13 | -$7.45M derived: sum of 4 quarters · filed 2021-08-13 | |
| 2020-03-31 | -$1.86M 10-Q · filed 2021-05-13 | -$4.33M derived: sum of 2 quarters · filed 2021-05-13 | -$4.71M derived: sum of 3 quarters · filed 2021-05-13 | -$5.33M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$2.85M derived: sum of 2 quarters · filed 2021-02-12 | -$3.47M derived: sum of 3 quarters · filed 2021-02-12 | -$3.55M 10-K · filed 2021-02-12 | |
| 2019-09-30 | -$378.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$995.20K derived: sum of 2 quarters · filed 2020-11-12 | -$1.08M 10-Q · filed 2020-11-12 | -$1.24M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$616.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$699.57K 10-Q · filed 2020-08-10 | -$859.07K derived: sum of 3 quarters · filed 2020-08-10 | ||
| 2019-03-31 | -$82.69K 10-Q · filed 2020-05-15 | -$242.18K derived: sum of 2 quarters · filed 2020-05-15 | |||
| 2018-12-31 | -$159.49K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$716.38K 10-K · filed 2020-03-12 | |||
| 2018-09-30 | -$556.89K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |